Drawing for CYTOSEN

USPTO serial 88048354

CYTOSEN

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
RATCLIFFE, ROBERT L
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with CYTOSEN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Matthew J. Smith

MATTHEW J. SMITH POLSINELLI PC100 SOUTH FOURTH STREETSUITE 1000ST. LOUIS, MO 63102

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of immuno oncological disorders, cancer, diabetes, respiratory, heart, neurological and auto immune disorders; stem cells for medical purposes; living cells for medical use; biological preparations for the treatment of cancer; therapeutic pharmaceuticals utilizing neural crest cells for use in the treatment of cancer, autoimmune disease and infectious diseases; Cell preparations, cellular vaccines and cellular biologics for the treatment of cancer and infectious diseases by autologous cell-based immunotherapyACTIVE—
042Scientific and technological services, namely, scientific research, design, analysis and testing in the field of cancer evolution and new cancer therapies using natural killer cells; industrial research in the field of new pharmaceutical products and new cancer therapies; medical and veterinary research services in the nature of the manipulation of cells within a laboratory or research facility to enable natural killer cells to be used for medical or therapeutic purposes; scientific research in the development of new cancer therapies; scientific research in human and animal cell therapy; scientific research into preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services; Conducting research and clinical trials for others relating to the use and the engineering of natural killer cells and cancer treatment and therapy; medical and scientific research in the field of cancer treatment and diagnosis; data collection for others for research purposes, namely, the collection, testing and research of patient molecular and genomic data; collection and preservation of human and animal DNA for research purposesACTIVE—
044Medical testing for diagnostic or treatment purposes in the field of cancer research; medical diagnostic testing, monitoring and reporting services; medical evaluation of immuno oncological disorders, cancer, diabetes, respiratory, heart, neurological and auto immune disorders; medical monitoring services; medical diagnostic, prognostic and theranostic screening and testing services; collection and preservation of dna for medical purposes; consulting services in the nature of providing medical information; consulting services in the field of healthcare and cancer diagnoses; providing a website featuring health and healthcare information related to cancer, testing and screening; genetic testing for medical purposes; providing information in the field of cancer prevention, screening, diagnosis and treatment for medical diagnostic and treatment purposes; providing genetics assessments in the nature of genetic counseling; genetic testing for medical diagnostic purposes; genomic testing for medical diagnostic purposes; Gene analysis and sequencing and DNA analysis and sequencing for medical diagnostic purposes and veterinary diagnostics purposes; gene analysis and sequencing and DNA analysis and sequencing for use in cancer diagnosis and treatment; providing a website featuring health and healthcare information related to cancer researchACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 23, 2020ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jul 6, 2020MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 6, 2020ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Dec 6, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 4, 2019EX1GSOU EXTENSION 1 GRANTED—
Dec 4, 2019EXT1SOU EXTENSION 1 FILED—
Dec 4, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 4, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Apr 9, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 9, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 20, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 5, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 5, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Mar 5, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Mar 5, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Mar 5, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Mar 4, 2019ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Feb 26, 2019PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Feb 14, 2019PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Feb 11, 2019ALIEASSIGNED TO LIE—
Jan 28, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 23, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 22, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 22, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 20, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 20, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 20, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 8, 2018DOCKASSIGNED TO EXAMINER—
Jul 26, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 26, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance